Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with alcohol use disorder and liver disease at a liver transplant center

在肝移植中心验证血液磷脂酰乙醇作为酒精使用障碍和肝病患者酒精摄入生物标志物的有效性

阅读:1

Abstract

BACKGROUND: Phosphatidylethanol (PEth), ethyl glucuronide (EtG), and ethyl sulphate (EtS) are highly sensitive and specific biomarkers of alcohol intake. This study investigated their application and relationship to traditional self-report measures in a mixed cohort of liver disease patients to guide decision making in liver transplant populations. METHODS: We recruited 183 participants (mean age 49.2 years, 62% male), with N = 99 liver disease (88% alcohol-associated liver disease [ALD]), N = 35 alcohol use disorder (AUD), and N = 49 healthy volunteers. Patient-reported alcohol intake and AUDIT score served as references and were compared to traditional biomarkers, PEth and serum EtG/EtS. Receiver operating characteristic (ROC) analysis and a range of biomarker cutoffs were examined to determine optimal test characteristics. A subset of blood samples modified to a standardized hematocrit analyzed the relationship between hematocrit and PEth. RESULTS: Compared to traditional biomarkers, both PEth and EtG were sensitive and specific for alcohol intake. At the limit of detection (LOD), PEth was 95% sensitive at detecting any drinking. PEth cutoff of 300 μg/L was 86% sensitive and 92% specific for "heavy drinking," and 600 μg/L was 88% sensitive and specific for "very heavy drinking." PEth displayed superior test characteristics (sensitivity, specificity, PPV, NPV, and AUC) to all measured traditional biomarkers over two-day and one-month time frames. A subset of participants suspected of drinking but reporting abstinence had positive PEth tests (35%), suggestive of unreported drinking. PEth was positively correlated with hematocrit (r(2) = 0.83, p < 0.01) and correction to a standardized median resulted in increases in PEth concentration in most cases. CONCLUSIONS: PEth is clinically useful as an alcohol biomarker in patients with liver disease and is superior to traditional biomarkers, providing good test characteristics for "heavy" and "very heavy" drinking using stepwise cutoffs. PEth detected a subset of patients underreporting their alcohol use, with implications for the management of patients in liver transplant clinics.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。